When prescribed and monitored by medical professionals, these treatments are safe and well-tolerated for many patients
Melanie Jay, director of the NYU Langone Comprehensive Program on Obesity Research, previously told TODAY.com
Allelic Variant in the Glucagon-like Peptide 1 Receptor Gene Associated with Greater Effect of Liraglutide and Exenatide on Gastric Emptying: A Pilot Pharmacogenetics Study. Neurogastroenterology and Motility: The Official Journal of the European Gastrointestinal Motility Society, vol
Clinical trials have shown that discontinuing treatment typically results in gradual weight regain and worsening glycemic control, underscoring that these are chronic disease management tools rather than short-term interventions
Who is not a good candidate for GLP-1
20229 N 67th Ave C1A Glendale, AZ 85308 Call Us: 602-595-7836 Hours Mon Thurs: 9am-5pm Come visit us